Dynasplint Therapy for Trismus in Head and Neck Cancer: Complete Statistical Analysis

1. Trial at a Glance

This page covers the registry results for Dynasplint Therapy for Trismus in Head and Neck Cancer (NCT00507208), a randomized na study. The primary outcome is Number of Participants Demonstrating Improved MIO Using Either the Dynapslint System or Tongue Depressors.

2. Clinical Question

This is a comparison of two approaches to improving mouth opening, with an outcome based on whether participants crossed a specified improvement threshold. The registry describes the trial as randomized, but does not report the method used to generate or conceal the random allocation. It also does not report a single comparison of the primary outcome, so the record does not establish how the outcome differed between treatment assignments. The control-arm crossover is relevant to interpretation: participants without improvement after 3 months could receive Dynasplint therapy, meaning their later outcomes may reflect exposure to both approaches rather than tongue depressors alone.

3. Trial Design

The registry describes a randomized, parallel-group trial with no masking. One group received the Dynasplint Trismus System; the control group used tongue depressors. The study is marked completed, and its phase is recorded as NA. The listed enrollment is 53. The registry record gives a start date of 2007-07 and a primary completion date of 2015-07.

The control-arm description specifies tongue-depressor use for 3 months, followed by crossover to Dynasplint if there was no improvement in mouth opening at that timepoint. This planned treatment change matters when considering outcomes measured later: the control assignment did not necessarily mean continued use of tongue depressors throughout follow-up. The primary outcome timeframe is 12 months, but the record does not describe the schedule of all measurements or how outcomes after crossover were handled analytically.

“Randomized” indicates that treatment assignment was intended to use random allocation, while “parallel” indicates that the trial compared groups assigned to different approaches. “No masking” means the record does not describe blinding of participants or study personnel. The registry record does not report details of the randomization procedure, allocation concealment, masking of outcome assessors, adherence, or deviations from assigned treatment. It also does not report a statistical analysis plan or describe whether the crossover was accounted for in the primary analysis. These omissions limit assessment of how the design was implemented and how the reported outcome, if analyzed, would relate to the original randomized comparison.

4. Participant Flow and Accounting

The registry reports how participants moved through each stage of the study. All counts below are exactly as posted; missing counts are not inferred from other stages.

Overall Study

5. Baseline Characteristics

The table reproduces the baseline characteristics posted in the registry, which describe the participants analysed at baseline and help show whether the randomized groups were comparable.

6. Primary Endpoint

The registry lists the primary outcome as Number of Participants Demonstrating Improved MIO Using Either the Dynapslint System or Tongue Depressors, measured over 12 months.

The primary endpoint counts participants who demonstrated improved maximal incisal opening (MIO). MIO is described as the distance between the tips of the upper and lower incisors when a participant makes a maximal effort to open the mouth. The registry defines successful improvement as an increase of > 5 mm from the baseline measurement, with assessment at 12 months.

A threshold-based endpoint converts a measurement into a classification: participants either meet the stated improvement criterion or do not. This can make the outcome easier to interpret as a count of participants reaching a defined degree of change. It also means the endpoint does not, by itself, show the full range of changes in mouth opening. A participant just below the threshold and one with no improvement may both be classified as not meeting the criterion, while the size of improvement among those who qualify is not conveyed by the count alone.

The registry record does not report a single primary-outcome comparison or an analysis result. It notes that the primary outcome has several categories or time points and was not reduced to one comparison. Therefore, the endpoint definition is available, but the posted results do not provide a single estimate of how many participants met the criterion in each assigned group or how those groups compared.

7. Why No Re-analysis Is Shown

8. Statistical Interpretation

9. Statistical Methods Explained

The registry describes the study as randomized, parallel, and unmasked. Random allocation is intended to make treatment groups comparable, on average, with respect to both measured and unmeasured characteristics. That protection depends on how the allocation process is implemented and on how participants are analyzed after assignment. The registry record does not report the randomization method, whether allocation was concealed, or the analysis population. The label “randomized” alone does not answer those questions.

What does the endpoint count?

The primary outcome is a binary classification based on change in MIO. A participant is counted as demonstrating improvement if MIO increases by > 5 mm from baseline; otherwise, the participant does not meet the stated success definition. Binary outcomes can be expressed as counts or as proportions within groups, and comparisons can be presented as differences or ratios of those proportions. Those approaches answer related but distinct questions. The registry record does not report a single primary-outcome comparison or any resulting estimate, so no such comparison can be interpreted from the posted results.

Converting a continuous measurement to a threshold has a trade-off. It offers a clear criterion for classifying improvement, but loses information about the magnitude and spread of individual changes. The registry record does not report group-level MIO changes or other summaries that would show how measurements were distributed around the threshold. The endpoint description also does not specify details such as how repeated measurements were handled or whether assessors were masked.

What would uncertainty estimates mean?

In general, a confidence interval describes a range of values compatible with the observed data under a statistical model. It conveys precision as well as the direction and scale of an estimated comparison. A narrow interval indicates greater precision than a wide interval, although interpretation also depends on the endpoint and the clinically relevant effect. A p-value, when reported, measures how incompatible the observed data are with a specified null model; it does not quantify the probability that a treatment works. Neither a confidence interval nor a p-value for the primary comparison is reported in the registry record.

For count-based outcomes, statistical methods may account for the number of participants contributing data and for the structure of the comparison. The choice of method should follow the study design and the prespecified analysis plan. The registry record does not report the statistical test, model, covariate adjustment, or analysis plan for the primary outcome. Therefore, it is not possible to assess whether an analysis used an appropriate model or whether any adjusted result differed from an unadjusted comparison.

How does crossover affect interpretation?

The control-arm description allows participants without improvement after 3 months to cross over to Dynasplint. An analysis by original randomized assignment would preserve the initial treatment comparison, but later treatment received could differ across participants assigned to the control arm. An analysis by treatment actually received would address a different question and could be affected by the reasons participants crossed over. These are general considerations, not descriptions of an analysis performed in this trial. The registry record does not report which approach was used or how crossover was handled.

Repeated outcome timepoints can also require a clear plan. Selecting or combining timepoints after examining results can affect the interpretation of statistical evidence. The record specifically notes that the primary outcome has several categories or time points and was not reduced to one comparison. It does not report which comparisons were intended to be primary, how they were selected, or whether results were adjusted for multiple testing.

What do the planning assumptions say?

The registry record describes sample-size calculations as planning illustrations based on the observed effect, rather than the trial’s own design. It states that the illustrations use a two-sided significance level of 0.05, equal allocation, and a normal approximation, with the effect to detect expressed as a fraction of the observed effect. Such calculations are planning aids: they describe the sample size that could be needed under stated assumptions. They are not observed power and do not establish the probability that the trial detected a real effect. The record does not report the trial’s original sample-size justification, and no primary-outcome analysis result is available to assess against those assumptions.

In general, over-dispersion matters when the variability in observed data exceeds what a simple statistical model assumes. A model that fails to account for this may produce uncertainty estimates that are too optimistic. Whether over-dispersion is relevant depends on the outcome and model used; the registry record does not report a primary-outcome model or diagnostics that would permit assessment in this trial.

10. Multiplicity, Missing Data and Analysis Populations

The registry notes that the primary outcome has several categories or time points and was not reduced to one comparison. When a study examines multiple outcomes, timepoints, or contrasts, the chance of finding an apparently notable result by chance can increase if those comparisons are treated as independent opportunities for success. Statistical plans may address this issue by identifying a primary comparison in advance or by adjusting how evidence is evaluated. The registry record does not report a multiplicity plan, a hierarchy of outcomes, or an adjustment method.

The record lists no analysis records, and the primary outcome is not presented as a single comparison. It therefore does not provide the group-specific primary-outcome counts, an effect estimate, or uncertainty measures needed to evaluate the primary question. The registry record also does not report an analysis population, such as whether all randomized participants were included according to their original assignment.

Missing outcome data can affect a comparison if participants with unavailable measurements differ systematically from those with observed measurements. Appropriate interpretation depends on how much data are missing, why they are missing, and what assumptions or methods are used. The registry record does not report missing-data counts, reasons for missingness, imputation, or sensitivity analyses. It also does not explain how the possible control-arm crossover was handled in outcome analyses. These omissions leave uncertainty about both the analysis population and the robustness of any primary-outcome result.

11. Safety Results

The registry reports serious adverse events as affected participants divided by participants at risk.

Other (non-serious) adverse events

Participants with at least one non-serious event at or above the registry's 5% reporting threshold.

Most frequent serious adverse event terms

Most frequent non-serious adverse event terms

Serious events with the highest arm-level rate: disease recurrence resulting in death (7.4%), esophageal stenosis (3.8%), dehydration (3.8%), pneumonia (3.8%), planned procedures prior to radiation tx (3.8%).

The registry reports serious adverse events as participants affected and participants at risk within each group. In the Dynasplint group, 11 of 27 participants at risk were recorded as affected; in the control group, 6 of 26 were recorded as affected. The registry also reports other adverse events affecting 9 of 27 participants in the Dynasplint group and 9 of 26 in the control group. These counts are descriptive. The record does not report a statistical comparison of adverse-event rates or establish that an event was caused by the assigned treatment.

The listed serious-event terms include disease recurrence resulting in death at 7.4%, esophageal stenosis at 3.8%, dehydration at 3.8%, pneumonia at 3.8%, planned procedures prior to radiation tx at 3.8%, and pneumothorax at 3.8%. The record does not give further context for these percentages in the adverse-event listing. Event terms and counts should not be interpreted as a causal assessment or as a complete account of clinical context. The registry record does not provide additional details on timing, severity grading, relatedness, or how events were distributed across treatment groups by term.

12. What the Result Does, and Does Not, Mean

The record establishes that a randomized comparison was registered between the Dynasplint Trismus System and tongue depressors for trismus in head and neck cancer. It defines the primary outcome as the number of participants whose MIO improved by > 5 mm from baseline, with a 12-month timeframe. It also describes a possible crossover from tongue depressors to Dynasplint for control-arm participants without improvement after 3 months.

Those details clarify the question the study was designed to address, but they do not supply its primary comparative result. The registry record notes that the primary outcome had several categories or time points and was not reduced to one comparison, and it lists no analysis records. As a result, the record does not show how many participants in each assigned group met the improvement criterion, how large the group difference was, or how precise an estimate would be. It does not support a conclusion that one approach was superior, that the approaches were equivalent, or that either approach had no effect.

The serious and other adverse-event counts describe recorded participants affected in each group. They do not by themselves establish a treatment-related safety difference, particularly in the absence of a comparative analysis and details on event timing and attribution. The listed event terms likewise should not be taken as evidence that the study approaches caused those events.

More generally, a completed trial record can still leave important questions unanswered when results or analysis details are absent. Here, interpretation is limited by the lack of a single primary-outcome comparison, the unreported analysis population and missing-data handling, and the unspecified treatment of crossover. The reported information is useful for understanding the design and the intended endpoint, but not for estimating the comparative primary-outcome effect.

13. Why This Trial Matters Statistically

This trial raises statistical issues that are common in randomized studies of clinical outcomes. First, the primary endpoint turns a measured change in mouth opening into a threshold-based success classification. That makes the criterion explicit, but the resulting count cannot show the full distribution of changes or how close participants were to the threshold. Continuous outcome summaries and the binary success count can answer complementary questions, but the registry record does not report the continuous summaries.

Second, the control-arm crossover complicates interpretation at the 12-month timeframe. The original randomized assignment and the treatment participants actually received may not remain the same throughout follow-up. A clear analysis plan is needed to specify whether the comparison concerns initial assignment or treatment received and how crossover is handled. The registry record does not report that plan.

Third, the primary outcome is described as having several categories or time points, yet no single comparison is reported. Without a prespecified primary contrast and an account of multiplicity, readers cannot determine which result was intended to carry the main inferential weight. The absence of analysis results also prevents assessment of effect size and precision, which are essential complements to any significance test.

The record therefore illustrates a central principle of trial interpretation: a design and endpoint description can clarify what investigators intended to compare, but they are not a substitute for a transparent analysis and result. Reporting the population analyzed, missing data, crossover handling, group-specific outcomes, and uncertainty estimates would be needed to interpret the primary comparison statistically.

14. Limitations

• The posted summary statistics are the only data these results rest on; patient-level data, full protocols and statistical analysis plans are not available.
• Recalculated results are simple, unadjusted calculations from posted summaries. They do not replace the sponsor's prespecified analysis.

The main trial-specific limitation in the registry record is that it does not report a single primary-outcome comparison. Although the endpoint and its 12-month timeframe are defined, the record says the outcome has several categories or time points and was not reduced to one comparison. No primary analysis result is listed. This prevents estimation of the comparative effect or its precision.

The control-arm crossover is another important limitation for interpretation. Participants without improvement after 3 months could cross over to Dynasplint, but the record does not say how crossover was handled in any analysis. It also does not report adherence, treatment discontinuation, or the extent to which participants followed their assigned approach.

The record does not describe eligibility criteria in detail, the randomization procedure, allocation concealment, or whether outcome assessors were masked. It gives no analysis population, missing-data counts or methods, or sensitivity analyses. The statistical plan, including the intended primary contrast and any multiplicity procedure, is not reported in the registry record. These gaps make it difficult to assess risk of bias or the robustness of a treatment comparison.

Safety reporting is also limited in detail. The registry gives affected-participant counts and selected serious-event terms, but does not report event timing, relatedness, or a statistical comparison. These limitations concern what is reported in the registry and should not be taken as proof that the trial collected no further information.

15. Related Tutorials

16. Related Statistical Calculators

17. Sources

• ClinicalTrials.gov: Dynasplint Therapy for Trismus in Head and Neck Cancer — NCT00507208.
• Registry record last updated 2016-09-13; status last verified 2016-08.
• Results first posted 2016-07-25.
• Data retrieved from ClinicalTrials.gov on 2026-11-09.
• Group sizes, means, event counts and sponsor-reported p-values are reproduced as posted. Effect estimates, confidence intervals and p-values not attributed to the sponsor are independently calculated from the posted summary statistics.

18. Record Summary

The registry record describes a completed, randomized, parallel-group trial without masking, comparing the Dynasplint Trismus System with tongue depressors for trismus in head and neck cancer. The control-arm description allows crossover to Dynasplint after 3 months if mouth opening has not improved. The primary endpoint is the number of participants with improved MIO at 12 months, defined as an increase of > 5 mm from baseline.

The record does not provide a single primary-outcome comparison or analysis results. It reports serious and other adverse-event counts by group, along with selected serious-event terms, but does not establish treatment causation or provide an inferential safety comparison. Key analysis details, including handling of crossover, missing data, and multiplicity, are not reported in the registry record.